Role of Dipeptidyl Peptidase-4 in Atherosclerotic Cardiovascular Disease in Humans and Animals with Chronic Stress

被引:8
作者
Piao, Limei [1 ]
Li, Yanglong [1 ]
Narisawa, Megumi [2 ]
Shen, Xionghu [3 ]
Cheng, Xian Wu [1 ]
机构
[1] Yanbian Univ Hosp, Dept Cardiol, 1327 Juzijie, Yanji 133000, Jilin, Peoples R China
[2] Nagoya Univ, Dept Cardiol, Grad Sch Med, Nagoya, Aichi, Japan
[3] Yanbian Univ Hosp, Dept Oncol, 1327 Juzijie, Yanji 133000, Jilin, Peoples R China
关键词
(Int Vascular senescence; Atherosclerosis; Inflammation; Oxidative stress; TYPE-2; DIABETES-MELLITUS; APOE-DEFICIENT MICE; MYOCARDIAL-INFARCTION; RECENT INSIGHTS; IV INHIBITION; RISK-FACTORS; INFLAMMATION; SITAGLIPTIN; EXENATIDE; MECHANISM;
D O I
10.1536/ihj.20-181
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Exposure to psychosocial stress is a risk factor for cardiovascular disease, including vascular atherosclerosis-based cardiovascular disease (ACVD). Dipeptidyl peptidase-4 (DPP-4) is a complex enzyme that acts as a membrane-anchored cell surface exopeptidase. DPP-4 is upregulated in metabolic and inflammatory cardiovascular disorders. DPP-4 exhibits many physiological and pharmacological functions by regulating its extremely abundant substrates, such as glucagon-like peptide-1 (GLP-1). Over the last 10 years, emerging data have demonstrated unexpected roles of DPP-4 in extracellular and intracellular signaling, immune activation, inflammation, oxidative stress production, cell apoptosis, insulin resistance, and lipid metabolism. This mini review focuses on recent novel findings in this field, highlighting a DPP-4-mediated regulation of GLP-1dependent and-independent signaling pathways as a potential therapeutic molecular target in treatments of chronic psychological stress-related ACVD in humans and animals.
引用
收藏
页码:470 / 478
页数:9
相关论文
共 50 条
  • [1] GENOMIC ORGANIZATION, EXACT LOCALIZATION, AND TISSUE EXPRESSION OF THE HUMAN CD26 (DIPEPTIDYL PEPTIDASE-IV) GENE
    ABBOTT, CA
    BAKER, E
    SUTHERLAND, GR
    MCCAUGHAN, GW
    [J]. IMMUNOGENETICS, 1994, 40 (05) : 331 - 338
  • [2] Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors
    Anderluh, Marko
    Kocic, Gordana
    Tomovic, Katarina
    Kocic, Radivoj
    Deljanin-Ilic, Marina
    Smelcerovic, Andrija
    [J]. PHARMACOLOGY & THERAPEUTICS, 2016, 167 : 100 - 107
  • [3] Perceived Stress in Myocardial Infarction Long-Term Mortality and Health Status Outcomes
    Arnold, Suzanne V.
    Smolderen, Kim G.
    Buchanan, Donna M.
    Li, Yan
    Spertus, John A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (18) : 1756 - 1763
  • [4] Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis
    Broxmeyer, Hal E.
    Hoggatt, Jonathan
    O'Leary, Heather A.
    Mantel, Charlie
    Chitteti, Brahmananda R.
    Cooper, Scott
    Messina-Graham, Steven
    Hangoc, Giao
    Farag, Sherif
    Rohrabaugh, Sara L.
    Ou, Xuan
    Speth, Jennifer
    Pelus, Louis M.
    Srour, Edward F.
    Campbell, Timothy B.
    [J]. NATURE MEDICINE, 2012, 18 (12) : 1786 - +
  • [5] Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
    Cosenso-Martin, Luciana Neves
    Takaoka, Lais Yumi
    Vilela-Martin, Jose Fernando
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 3221 - 3229
  • [6] Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
    Deacon, Carolyn F.
    [J]. PEPTIDES, 2020, 125
  • [7] Molecular characterization of dipeptidyl peptidase activity in serum -: Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides
    Durinx, C
    Lambeir, AM
    Bosmans, E
    Falmagne, JB
    Berghmans, R
    Haemers, A
    Scharpé, S
    De Meester, I
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (17): : 5608 - 5613
  • [8] Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
    Ferrannini, Ele
    DeFronzo, Ralph A.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (34) : 2288 - U19
  • [9] A Multicenter Observational Study of Incretin-based Drugs and Heart Failure
    Filion, Kristian B.
    Azoulay, Laurent
    Platt, Robert W.
    Dahl, Matthew
    Dormuth, Colin R.
    Clemens, Kristin K.
    Hu, Nianping
    Paterson, J. Michael
    Targownik, Laura
    Turin, Tanvir C.
    Udell, Jacob A.
    Ernst, Pierre
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (12) : 1145 - 1154
  • [10] Saxagliptin Prevents Increased Coronary Vascular Stiffness in Aortic-Banded Mini Swine
    Fleenor, Bradley S.
    Ouyang, An
    Olver, T. Dylan
    Hiemstra, Jessica A.
    Cobb, Melissa S.
    Minervini, Gianmaria
    Emter, Craig A.
    [J]. HYPERTENSION, 2018, 72 (02) : 466 - 475